Implantable Charging Station Boosts Cancer-Fighting Immune Cells

UCLA researchers develop a device that acts as a support hub for engineered immune cells, helping them stay active and continue attacking cancer.

Mar. 18, 2026 at 6:42am

Got story updates? Submit your updates here. ›

Researchers at UCLA have developed an implantable device that acts like a support hub for engineered immune cells, helping them stay active and continue attacking cancer. The device uses tiny biomimetic particles to reactivate and support chimeric antigen receptor-invariant natural killer T cells (CAR-iNKT cells), which have shown promise in early studies but often lose potency after delivery to a patient's body. The implanted device attracts these immune cells and provides sustained signals that help them stay active, multiply, and form long-term memory.

Why it matters

Immunotherapy has transformed cancer treatment, but engineered immune cells often lose strength quickly after entering the body, especially in tumor environments that suppress immune activity. This new implantable device aims to address this challenge by providing a localized 'charging station' to keep the cancer-fighting immune cells active and effective.

The details

The device contains tiny biomimetic particles designed to mimic activation signals for iNKT cells. When the CAR-iNKT cells connect to these particles, it sets off a series of molecular signals that reactivate the cells and send them back out to destroy cancer cells. The particles are also coated with capsules containing a signaling protein (IL-15) that supports cell proliferation. Researchers spent significant time optimizing the strength of the activation signals, the amount of growth-supporting protein released, and the physical properties of the material to maintain the right level of immune activity without exhausting the cells.

  • The study demonstrating the platform's efficacy was published on March 18, 2026.

The players

Song Li

Chancellor's professor of bioengineering at the UCLA Samueli School of Engineering and co-leader of the study.

Lili Yang

UCLA professor of microbiology, immunology & molecular genetics and co-leader of the study.

Yan-Ruide "Charlie" Li

Postdoctoral scholar of microbiology, immunology & molecular genetics at UCLA and first author of the study.

Tzung Hsiai

UCLA Samueli bioengineering professor, professor-in-residence at the David Geffen School of Medicine at UCLA, and co-author of the paper.

UCLA

The university where the research was conducted.

Got photos? Submit your photos here. ›

What they’re saying

“These engineered microparticles are where CAR-iNKT cells recharge and switch back into attack mode. Instead of delivering a one-time boost, the device provides sustained signals that help the cells stay active, multiply and form long-term memory.”

— Song Li, Chancellor's professor of bioengineering at the UCLA Samueli School of Engineering

“It's similar in concept to plugging your phone into a charging cable. In this case, the CAR-iNKT cells connect to the TCR antigen, which sets off a series of molecular signals that activate them, sending them back out to destroy cancer cells.”

— Yan-Ruide "Charlie" Li, Postdoctoral scholar of microbiology, immunology & molecular genetics at UCLA

“This approach significantly improves the durability and effectiveness of CAR-iNKT cell responses in both solid tumor and systemic blood cancer models, offering a new strategy to strengthen cell-based cancer therapies and expand their clinical potential.”

— Lili Yang, UCLA professor of microbiology, immunology & molecular genetics

What’s next

The team is continuing to refine the system and explore how it could support additional cancer immunotherapies.

The takeaway

This implantable 'charging station' for cancer-fighting immune cells represents a promising new approach to boosting the durability and effectiveness of cell-based immunotherapies, which could significantly expand their clinical potential in treating solid tumors and blood cancers.